Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 10/20 | 0.45 |
| ▸ | HTR2A | P28223 | 4/20 | 0.41 |
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8066115 | 1.00 | NFE2L2 (0.45) | NFE2L2HTR2AHTR2CKCNH2PTGS1 | |
| SCHEMBL11819766 | 1.00 | NFE2L2 (0.45) | NFE2L2HTR2AHTR2CKCNH2PTGS1 | |
| SCHEMBL8054612 | 0.81 | NFE2L2 (0.46) | NFE2L2HTR2AHTR2CKCNH2PTGS1 | |
| SCHEMBL8054609 | 0.81 | NFE2L2 (0.46) | NFE2L2HTR2AHTR2CKCNH2PTGS1 | |
| SCHEMBL8054617 | 0.81 | NFE2L2 (0.46) | NFE2L2HTR2AHTR2CKCNH2PTGS1 | |
| SCHEMBL8068813 | 0.79 | NFE2L2 (0.44) | NFE2L2HTR2AHTR2CKCNH2NQO2 | |
| SCHEMBL8068816 | 0.79 | NFE2L2 (0.44) | NFE2L2HTR2AHTR2CKCNH2NQO2 | |
| SCHEMBL8054621 | 0.77 | ERN1 (0.38) | PTGS1PTGS2 | |
| SCHEMBL8064075 | 0.75 | ATM (0.38) | — | |
| SCHEMBL8054634 | 0.73 | PDE7A (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6020379-A | Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia | CELL PATHWAYS, INC. (US) | 2000-02-01 | — | — | US | disclosed |